Squarepoint’s BioMarin Pharmaceuticals BMRN Stock Holding History

Squarepoint’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,900	Closed	-$410K	–	4297
2025 Q4	$410K	Sell	6,900 -27,100	-80%	-$1.48M	﹤0.01%	3364
2025 Q3	$1.84M	Sell	34,000 -18,500	-35%	-$1.06M	﹤0.01%	2172
2025 Q2	$2.89M	Buy	52,500 +30,800	+142%	+$1.81M	﹤0.01%	1829
2025 Q1	$1.53M	Sell	21,700 -57,100	-72%	-$3.84M	﹤0.01%	2304
2024 Q4	$5.18M	Sell	78,800 -16,200	-17%	-$1.09M	0.01%	1603
2024 Q3	$6.68M	Buy	95,000 +49,900	+111%	+$4.17M	0.01%	1223
2024 Q2	$3.71M	Buy	45,100 +42,500	+1,635%	+$3.54M	0.01%	1587
2024 Q1	$227K	Sell	2,600 -27,600	-91%	-$2.47M	﹤0.01%	3547
2023 Q4	$2.91M	Buy	+30,200	New	+$2.67M	0.01%	1754
2022 Q1	–	Sell	-6,100	Closed	-$539K	–	2846
2021 Q4	$539K	Buy	+6,100	New	+$503K	﹤0.01%	2094

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Squarepoint's BMRN Position: Q2 2026 in Review

Squarepoint reduced its BioMarin Pharmaceuticals (BMRN) stake by 71% in Q2 2026, selling an estimated $13.9M and leaving 105,968 shares worth $6.06M. The position accounts for 0.01% of the portfolio, ranked #1440.

Squarepoint first reported a position in BMRN in Q1 2015 and has held it in 36 quarters since. The position peaked at $109M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Squarepoint held 105,968 shares of BioMarin Pharmaceuticals worth $6.06M as of Q2 2026.
Squarepoint sold 253,734 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $13.9M.
BioMarin Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1440 holding.
Squarepoint first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 36 quarters since.
Squarepoint's BioMarin Pharmaceuticals position peaked at $109M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.